Recent Articles By The Author
These companies are trading at reasonable multiples and two are offering nice dividend yields, too.
CRBP has topline Phase 3 data for its primary compound Lenabasum for Systemic Sclerosis due out this summer.
Various hard-charging mega-cap stocks seem overdue for a significant pause, while a drop in Acadia Pharmaceuticals sets up an options play.
The biotech is Paratek Pharmaceuticals and it presents itself as a good covered call play.
The market seems to be overlooking this trio of potential setbacks to stocks.
Concerns over the strength of the recovery in the jobs market and the rate of Covid-19 cases are reasons for caution despite a resurgent market.